Inhalation interferon beta sNG001 reduces the risk of COVID-19 developing into severe illness.

Synairgen, !---- a pharmaceutical company, announced today that its inhaled interferon beta sNG001 treatment of patients with COVID-19 significantly reduces the risk of serious illness compared to a placebo"The results confirm that inhaled interferon beta restores the lung immune response, enhances immune protection, accelerates recovery and resists the effects of the SARS-CoV-2 virus," said Tom Wilkinson, lead research fellow at synairgen, apharmaceutical companyresults showed that patients who received SNG001 had a 79 percent lower risk of developing a serious illness on the first day to the 16th day of treatment than patients treated with a placebo, patients treated with SNG001 were more than twice as likely to recover throughout the treatment than in the placebo groupinterferon is a host-specific glycoprotein secreted by animal cells with antiviral functions after being infected with certain virusesthe interferons secreted by cells infected with the virus can act with receptors associated with the surrounding uninfected cells, prompting these cells to synthesize antiviral proteins to prevent further infection, thus acting as an antiviral.